Skip to main content

Advertisement

Log in

The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

Carcinoembryonic antigen (CEA) estimations are used to facilitate early diagnosis of recurrent disease after treatment for colorectal cancer. PURPOSE: This study was designed to determine the natural history of patients with normal and abnormal levels of CEA. METHODS: Patients undergoing potentially curative resection of colorectal tumors (Dukes Stage A-C) entered a prospective, randomized trial comparing two follow-up regimens (to be reported separately) had CEA levels measured every 3 months for two years; then every 6 months for the next three years. In the study protocol, a rise in CEA was not an indication for investigation to determine recurrence unless there was also other evidence of recurrent disease. RESULTS: Three hundred eleven patients were followed for a median of 4.5 (range, 2–5) years. Recurrent disease developed in 98 (32 percent) patients, 57 of whom had an elevated CEA (sensitivity 58 percent), with a median lead time of six (range, 1–30) months from first abnormal CEA to diagnosis of recurrent disease by other means. The specificity, positive predictive value, and negative predictive value of CEA as an indicator of subsequent recurrent disease was 93 percent, 79 percent, and 83 percent, respectively. The sensitivity of CEA for predicting hepatic metastases was 80 percent, with a median lead time of eight (range, 1–30) months, compared with only 46 percent for sites of recurrent disease other than the liver. CONCLUSIONS: CEA was the first indicator of recurrent disease in 58 percent of all patients and in 80 percent of patients with liver metastases. The diagnosis of recurrent disease may be made several months earlier by investigating the first abnormal CEA level, although any benefit in terms of survival remains to be proven.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Gold P, Freedman SO. Demonstration of tumorspecific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965;121:439–62.

    PubMed  Google Scholar 

  2. Cutait R, Alves VAF, Lopez LC,et al. Restaging of colorectal cancer based on of CEA and cytokeratins. Dis Colon Rectum 1991;34:917–20.

    PubMed  Google Scholar 

  3. Hine KR, Leonard JC, Booth SN, Dykes PW. Carcinoembryonic antigen concentrations in undiagnosed patients. Lancet 1978;2:1337–40.

    PubMed  Google Scholar 

  4. Goldberg DM, Sharkey RM, Primus FJ. Immunohistochemical detection of carcinoembryonic antigen in conventional histopathology specimens. Cancer 1978;42:546–53.

    Google Scholar 

  5. Bhatavdeker JM, Patel DD, Giri DD,et al. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of the colon and rectum. Br J Cancer 1992;66:977–80.

    PubMed  Google Scholar 

  6. Devesa JM, Morales V, Enriquez JM,et al. Colorectal cancer. The bases for a comprehensive follow-up. Dis Colon Rectum 1988;31:636–52.

    PubMed  Google Scholar 

  7. Wanebo HJ, Llaneras M, Martin T, Kaiser D. Prospective monitoring trial for carcinoma of colon and rectum after surgical resection. Surg Gynecol Obstet 1989;169:479–87.

    PubMed  Google Scholar 

  8. Schiessel R, Wunderlich M, Herbst F. Local recurrence of colorectal cancer: effect of early detection and aggressive surgery. Br J Surg 1986;73:342–4.

    PubMed  Google Scholar 

  9. Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operation based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 1985;149:198–204.

    PubMed  Google Scholar 

  10. Minton JP, Hoehn JL, Gerber DM,et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985;55:1284–90.

    PubMed  Google Scholar 

  11. Wilking N, Petrelli NJ, Herrera L, Holyoke ED, Mittelman A. Abdominal exploration for suspected recurrent carcinoma of the colon and rectum based upon elevated carcinoembryonic antigen alone or in combination with other diagnostic methods. Surg Gynecol Obstet 1986;162:465–8.

    PubMed  Google Scholar 

  12. McLeish JA, Giles GG, Thursfield V. Investigation, follow-up and recurrence after resection of colorectal cancer. Aust N Z J Surg 1992;62:931–40.

    PubMed  Google Scholar 

  13. Kelly CJ, Daly JM. Colorectal cancer. Principles of postoperative follow-up. Cancer 1992;70:1397–408.

    PubMed  Google Scholar 

  14. Beart RW, Metzger PP, O'Connell MJ, Schutt AJ. Postoperative screening of patients with carcinoma of the colon. Dis Colon Rectum 1981;24:585–9.

    PubMed  Google Scholar 

  15. Martin EW, Minton JP, Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985;202:310–6.

    PubMed  Google Scholar 

  16. Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the mangement of colorectal carcinoma. World J Surg 1984;8:279–86.

    PubMed  Google Scholar 

  17. Denstman F, Rosen L, Khubchandani IT, Sheets JA, Stasik JJ, Riether RD. Comparing predictive decision rules in postoperative CEA monitoring. Cancer 1986;58:2089–95.

    PubMed  Google Scholar 

  18. O'Dwyer PJ, Mojzisik C, McCabe DP, Farrar WB, Carey LC, Martin EW. Reoperation directed by carcinoembryonic antigen level: the importance of a thorough preoperative evaluation. Am J Surg 1988;155:227–31.

    PubMed  Google Scholar 

  19. Barillari P, Sammartino P, Cardi M,et al. Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA, and Ca 1:9-9 evaluation in the early diagnosis of recurrence. Aust N Z J Surg 1991;61:675–80.

    PubMed  Google Scholar 

  20. Hine FR, Dyke PW. Serum CEA testing in the postoperative surveillance of colorectal carcinoma. Br J Surg 1984;49:689–93.

    Google Scholar 

  21. Welsh JP, Donaldson GA. Detection and treatment of recurrent cancer of the colon and rectum. Am J Surg 1978;135:505–11.

    PubMed  Google Scholar 

  22. Malcolm AW, Perencevich NP, Olson RN, Hanley JA, Chaffey JT, Wilson RE. Analysis of recurrence patterns following curative resection for carcinoma of the colon and rectum. Surg Gynecol 1981;152:131–6.

    PubMed  Google Scholar 

  23. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 1984;3:303–24.

    PubMed  Google Scholar 

  24. Northover JM. Carcinoembryonic antigen and recurrent colorectal cancer. Br J Surg 1985;72(Suppl):S44–6.

    PubMed  Google Scholar 

  25. Tate H. Plasma CEA in the post-surgical management of colorectal carcinoma. Br J Cancer 1982;46:323–30.

    PubMed  Google Scholar 

  26. Mandel JS, Bond JH, Church TR,et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993;328:1365–71.

    PubMed  Google Scholar 

  27. Herfarth C, Schlag P, Hohenberger P. Surgical strategies in locoregional recurrences of gastrointestinal carcinoma. World J Surg 1987;11:504–10.

    PubMed  Google Scholar 

  28. Moertel CG, Schut AJ, Go VL. Carcinoembryonic antigen test for recurrent colorectal carcinoma: inadequacy for early detection. JAMA 1978;239:1065–6.

    PubMed  Google Scholar 

  29. Sugarbaker PH, Gianola FJ, Dwyer A, Neuman, NR. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79–87.

    PubMed  Google Scholar 

  30. Gordon PH. Malignant neoplasms of the colon. In: Gordon PH, Nivatvongs S, eds. Principles and practice of surgery for the colon, rectum, and anus. St. Louis: Quality Medical Publishing, 1992:501–90.

    Google Scholar 

  31. Rocklin MS, Senagore AJ, Talbott TM. Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma. Dis Colon Rectum 1991;34:794–7.

    PubMed  Google Scholar 

  32. Black R. Hepatic metastases during follow-up. Results from the FMC/RGH trial. Proceedings of the ASC Adelaide: Royal Australasian College of Surgeons 1993; May, p192.

  33. Camunas J, Enriquez JM, Devesa JM, Morales V, Millan I. Value of follow-up in the management of recurrent colorectal cancer. Eur J Surg Oncol 1991;17:530–5.

    PubMed  Google Scholar 

  34. Steele GJ. Follow-up plans after treatment of primary colon and rectum cancer. World J Surg 1991;15:583–8.

    PubMed  Google Scholar 

  35. Fleischer DE, Goldgerg SB, Browning TH,et al. Detection and surveillance of colorectal cancer. JAMA 1989;261:580–5.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by a grant from the Anti-Cancer Foundation of the Universities of South Australia.

Read at the Annual Scientific Congress of the Royal Australasian College of Surgeons, Adelaide, South Australia, May 9 to 14, 1993.

About this article

Cite this article

McCall, J.L., Black, R.B., Rich, C.A. et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis Colon Rectum 37, 875–881 (1994). https://doi.org/10.1007/BF02052591

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02052591

Key words

Navigation